Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Lanatoside C. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 12/20 | 0.71 |
| ▸ | ATP1B1 known ✓ | P05026 | 12/20 | 0.71 |
| ▸ | ATP1A2 known ✓ | P50993 | 12/20 | 0.71 |
| ▸ | ATP1B2 known ✓ | P14415 | 11/20 | 0.71 |
| ▸ | ATP1B3 known ✓ | P54709 | 11/20 | 0.71 |
| ▸ | ATP1A3 known ✓ | P13637 | 1/20 | 0.71 |
| ▸ | FXYD2 known ✓ | P54710 | 1/20 | 0.71 |
| ▸ | ATP1A4 known ✓ | Q13733 | 1/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanatoside C SCHEMBL18947801 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL20582682 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL18223891 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL18277653 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL18364709 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL23054706 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| Lanatoside C SCHEMBL15959375 | 1.00 | PAX8 (1.00) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL18949552 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL24837992 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB | |
| SCHEMBL20251039 | 0.97 | PAX8 (0.94) | PAX8LMNATP53SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2422 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| EP-3730131-B1 | TREATMENT OF BRAIN CANCER BY CONTINUOUS INFUSION OF COENZYME Q10 | BPGBIO INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2025123147-A1 | TOLERIZING IMMUNOMODULATORY COMBINATION | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2025-06-19 | — | — | WO | claimed |
| WO-2025120106-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AN AVIAN EMBRYO CELLS | SUPRÊME (FR) | 2025-06-12 | — | — | WO | claimed |
| EP-4567102-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS | Suprême (FR) | 2025-06-11 | — | — | EP | claimed |
| EP-4558612-A1 | METHODS AND COMPOSITIONS FOR GENERATING ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| WO-2003099320-A1 | NEUREGULIN BASED METHODS AND COMPOSITIONS FOR TREATING VIRAL MYOCARDITIS AND DILATED CARDIOMYOPATHY | ZENSUN (SHANGHAI) SCI-TECH.LTD (CN) | 2003-12-04 | — | — | WO | claimed |
| WO-2003099300-A1 | NEUREGULIN BASED METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES | ZENSUN (SHANGHAI) SCI-TECH, LTD. (CN) | 2003-12-04 | — | — | WO | claimed |
| CN-2329059-Y | Quick look-up instrument for incompatibility of drugs in a prescription of 159 kind of injections | GU CHUNWEI (CN) | 1999-07-14 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5545623-A | ADMINISTERING DIGITALIS DERIVATIVES | Matsumori, Akira (JP) | 1996-08-13 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-4198391-A | CARDIAC GLYCOSIDE, ETHANOL, WATER, PROPYLENE GLYCOL OR GLYCERINE, POLYOXYETHYLENE GLYCOL | R. P. SCHERER LTD. (GB) | 1980-04-15 | — | — | US | claimed |
| US-4067960-A | GELATIN CAPSULE, CARDIOTONIC | R. P. SCHERER LIMITED (EN) | 1978-01-10 | — | — | US | claimed |